1. Suerbaum S, Michetti P.
Helicobacter pylori infection. N Engl J Med 2002;347:1175–1186.
2. IARC. Schistosomes, liver flukes and
Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1–241.
3. Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of
H. pylori therapy. Gut 2022;71:643–650.
5. Kim SE, Park MI, Park SJ, et al. Second-line bismuth-containing quadruple therapy for
Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017;23:1059–1066.
6. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of
Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493–496.
7. Kim N. The rescue therapy in the Helicobacter pylori treatment failure. Korean J Helicobacter Up Gastrointest Res 2007;7:1–7.
8. Argueta EA, Moss SF. How we approach difficult to eradicate
Helicobacter pylori. Gastroenterology 2022;162:32–37.
9. Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of
Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter 2019;24:e12592.
11. Lee JW, Kim N, Choi SI, et al. Prevalence and trends of multiple antimicrobial resistance of
Helicobacter pylori in one tertiary hospital for 20 years in Korea. Helicobacter 2023;28:e12939.
12. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of
Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248–253.
13. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of
Helicobacter pylori. Gastroenterology 1996;111:886–900.
14. Scott D, Weeks D, Melchers K, Sachs G. The life and death of
Helicobacter pylori. Gut 1998;43 Suppl 1:S56–S60.
15. Jung HK, Kang SJ, Lee YC. Evidence-based guidelines for the treatment of
Helicobacter pylori infection in Korea: 2020 revised edition. Korean J
Helicobacter Up Gastrointest Res 2020;20:261–287.
16. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of
Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6–30.
17. Lim JH, Kim SG, Song JH, et al. Efficacy of levofloxacin-based third-line therapy for the eradication of
Helicobacter pylori in peptic ulcer disease. Gut Liver 2017;11:226–231.
18. Malfertheiner P, Megraud F, Rokkas T, et al. Management of
Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022;71:1724–1762.
19. Gisbert JP, Romano M, Gravina AG, et al.
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuthcontaining quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015;41:768–775.
20. Hsu PI, Wu DC, Chen A, et al. Quadruple rescue therapy for
Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008;38:404–409.
21. Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for
Helicobacter pylori infection. Am J Gastroenterol 2002;97:857–860.
22. Kim YJ, Chung WC. Bismuth-containing standard triple therapy the first-line eradication therapy for Helicobacter pylori. Korean J Helicobacter Up Gastrointest Res 2021;21:354–358.
23. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for
Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311–316.
24. Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of
Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2022;23:201–210.
25. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to
Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12:317–323.
26. Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for
Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter 2020;25:e12692.
27. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on
Helicobacter pylori eradication. Aliment Pharmacol Ther 2017;46:106–114.
28. Zhang M, Pang M, Zhang M. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as
Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Clinics (Sao Paulo) 2022;77:100058.
30. Choi YJ, Lee YC, Kim JM, et al. Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for firstline treatment of
Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial. Gut Liver 2022;16:535–546.
31. Kim SE, Hwang JH. Management of
Helicobacter pylori infection: a comparison between Korea and the United States. Gut Liver 2022;16:503–514.